HIV/AIDS Vaccine Research

  • Ruanne V. Barnabas
  • Ann C. Duerr
  • Judith N. Wasserheit


The scale of the HIV epidemic in the last 25 years has been staggering: today there are 39.5 million people living with HIV, with more than 4 million new infections occurring every year (UNAIDS, 2006). The majority of new HIV infections worldwide occur in developing countries, where the brunt of the epidemic lies and one in four people are infected in the most severely affected regions. Many of them are young adults in their economically most productive years (UNAIDS, 2006). Here the scale of the pandemic threatens the very fabric of society.

In tackling the burden of infectious diseases, effective vaccines are the only measure that has resulted not only in significant inroads into disease elimination and control but also disease eradication. While the best examples of vaccine successes are for viral infections such as polio and measles, vaccines against a range of other bacterial and viral pathogens have resulted in more than 98% reduction in diseases such as diphtheria,...


Viral Load Vaccine Efficacy Sexual Debut Sexually Transmitted Disease Vaccine Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are grateful to Katie Skibinski for technical and editorial assistance with the chapter.


  1. AAV vector has excellent safety profile: Dr. Excler (2005, Feb 17, 2005). The Hindu. Scholar
  2. Abbott, J., Johnson, R., Koziol-McLain, J., & Lowenstein, S. R. (1995). Domestic violence against women. Incidence and prevalence in an emergency department population. Jama, 273(22), 1763–1767.PubMedCrossRefGoogle Scholar
  3. Abu-Raddad, L. J., Patnaik, P., & Kublin, J. G. (2006). Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science, 314(5805), 1603–1606.PubMedCrossRefGoogle Scholar
  4. Adolescent Medicine Trials Network. (2007). Connect to Protect, 2007, from http:// Scholar
  5. Anzala, A. O., Simonsen, J. N., Kimani, J., Ball, T. B., Nagelkerke, N. J., Rutherford, J., et al. (2000). Acute sexually transmitted infections increase human immunodeficiency virus type 1 plasma viremia, increase plasma type 2 cytokines, and decrease CD4 cell counts. J Infect Dis, 182(2), 459–466.PubMedCrossRefGoogle Scholar
  6. Auvert, B., Buve, A., Ferry, B., Carael, M., Morison, L., Lagarde, E., et al. (2001). Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. Aids, 15(Suppl 4), S15–30.PubMedCrossRefGoogle Scholar
  7. Averhoff, F., Linton, L., Peddecord, K. M., Edwards, C., Wang, W., & Fishbein, D. (2004). A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. Am J Public Health, 94(6), 978–984.PubMedCrossRefGoogle Scholar
  8. Baeten, J. M., Richardson, B. A., Martin, H. L., Jr., Nyange, P. M., Lavreys, L., Ngugi, E. N., et al. (2000). Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. J Acquir Immune Defic Syndr, 24(5), 458–464.PubMedGoogle Scholar
  9. Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., et al. (2007). Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet, 369(9562), 643–656.PubMedCrossRefGoogle Scholar
  10. Baptiste, D. R., Bhana, A., Petersen, I., McKay, M., Voisin, D., Bell, C., et al. (2006). Community collaborative youth-focused HIV/AIDS prevention in South Africa and Trinidad: preliminary findings. J Pediatr Psychol, 31(9), 905–916.PubMedCrossRefGoogle Scholar
  11. Block, S. L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K. E., Marchant, C. D., et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118(5), 2135–2145.PubMedCrossRefGoogle Scholar
  12. Buchacz, K., Patel, P., Taylor, M., Kerndt, P. R., Byers, R. H., Holmberg, S. D., et al. (2004). Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. Aids, 18(15), 2075–2079.PubMedCrossRefGoogle Scholar
  13. Burton, D. R., Stanfield, R. L., & Wilson, I. A. (2005). Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A, 102(42), 14943–14948.PubMedCrossRefGoogle Scholar
  14. Cardinali, M., Lau, C.-Y., Lawrence, D., Allen, M., & Sheets, R. (2007). Considerations for HIV Vaccine Clinical Trials in Adolescents: NIAID, NIH. (Accessed November 15, 2007); AdolescentsPaper.pdf.Google Scholar
  15. Carpenter, L. M., Kamali, A., Ruberantwari, A., Malamba, S. S., & Whitworth, J. A. (1999). Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. Aids, 13(9), 1083–1089.PubMedCrossRefGoogle Scholar
  16. Carvalho, M., de Carvalho, S., Pannuti, C. S., Sumita, L. M., & de Souza, V. A. (1998). Prevalence of herpes simplex type 2 antibodies and a clinical history of herpes in three different populations in Campinas City, Brazil. Int J Infect Dis, 3(2), 94–98.PubMedCrossRefGoogle Scholar
  17. CDC. (2003). Guidelines for maintaining and managing the vaccine cold chain. MMWR Morb Mortal Wkly Rep, 52(42), 1023–1025.Google Scholar
  18. CDC. (2007). AIDS Surveillance – General Epidemiology (Through 2005). Retrieved 02/27/07, 2007, from epidemiology/index.htmGoogle Scholar
  19. Chuenchitra, T., Sukwit, S., Gaywee, J., Viputtikul, K., Eamsila, C., Tabprasit, S., et al. (2005). The development of HIV research laboratories in the Royal Thai Army Medical Department. J Med Assoc Thai, 88(Suppl 3), S317–324.PubMedGoogle Scholar
  20. Cleghorn, F., Pape, J. W., Schechter, M., Bartholomew, C., Sanchez, J., Jack, N., et al. (2007). Lessons from a multi-site international trial in the Caribbean and South America of an HIV-1 canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rpg120. manuscript.Google Scholar
  21. Cohen, J. (2005). AIDS clinical trials. More woes for novel HIV prevention approach. Science, 307(5716), 1708.PubMedCrossRefGoogle Scholar
  22. Cohen, M. S., Hoffman, I. F., Royce, R. A., Kazembe, P., Dyer, J. R., Daly, C. C., et al. (1997). Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet, 349(9069), 1868–1873.PubMedCrossRefGoogle Scholar
  23. Colgrove, J. (2006). The ethics and politics of compulsory HPV vaccination. N Engl J Med, 355(23), 2389–2391.PubMedCrossRefGoogle Scholar
  24. Coombs, R. W., Reichelderfer, P. S., & Landay, A. L. (2003). Recent observations on HIV type-1 infection in the genital tract of men and women. Aids, 17(4), 455–480.PubMedCrossRefGoogle Scholar
  25. Corey, L., Wald, A., Celum, C. L., & Quinn, T. C. (2004). The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr, 35(5), 435–445.PubMedCrossRefGoogle Scholar
  26. Da'Dara, A. A., Lautsch, N., Dudek, T., Novitsky, V., Lee, T. H., Essex, M., et al. (2006). Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Vaccine, 24(24), 5211–5219.PubMedCrossRefGoogle Scholar
  27. Daley, M. F., Liddon, N., Crane, L. A., Beaty, B. L., Barrow, J., Babbel, C., et al. (2006). A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics, 118(6), 2280–2289.PubMedCrossRefGoogle Scholar
  28. Day, J. H., Grant, A. D., Fielding, K. L., Morris, L., Moloi, V., Charalambous, S., et al. (2004). Does tuberculosis increase HIV load? J Infect Dis, 190(9), 1677–1684.PubMedCrossRefGoogle Scholar
  29. Douek, D. C., Kwong, P. D., & Nabel, G. J. (2006). The rational design of an AIDS vaccine. Cell, 124(4), 677–681.PubMedCrossRefGoogle Scholar
  30. Duerr, A., Wasserheit, J. N., & Corey, L. (2006). HIV vaccines: new frontiers in vaccine development. Clin Infect Dis, 43(4), 500–511.PubMedCrossRefGoogle Scholar
  31. Duffus, W. A., Mermin, J., Bunnell, R., Byers, R. H., Odongo, G., Ekwaru, P., et al. (2005). Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS, 16(11), 733–735.PubMedCrossRefGoogle Scholar
  32. Dunkle, K. L., Jewkes, R. K., Brown, H. C., Yoshihama, M., Gray, G. E., McIntyre, J. A., et al. (2004). Prevalence and patterns of gender-based violence and revictimization among women attending antenatal clinics in Soweto, South Africa. Am J Epidemiol, 160(3), 230–239.PubMedCrossRefGoogle Scholar
  33. Erickson, A. (2004). For HIV vaccine trials, size does matter. Nature Medicine, 10, 111.PubMedCrossRefGoogle Scholar
  34. Excler, J. L. (2006). AIDS vaccine efficacy trials: expand capacity and prioritize. `Throughout Africa, Asia and Latin America state-of-the-art clinics and laboratories … exist where, 4 years ago, there were none'. Expert Rev Vaccines, 5(2), 167–170.PubMedCrossRefGoogle Scholar
  35. FDA. (2004a). Good Clinical Practice from ClinPractice.htmGoogle Scholar
  36. FDA. (2004b). Good Laboratory Practice from DSI/goodClinPractice.htmGoogle Scholar
  37. Fernandez, E., Betriu, M. A., Gomez, R., & Montoliu, J. (1996). Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant, 11(8), 1559–1563.PubMedGoogle Scholar
  38. Ferrantelli, F., Butto, S., Cafaro, A., Wahren, B., & Ensoli, B. (2006). Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. Springer Semin Immunopathol, 28(3), 289–301.PubMedCrossRefGoogle Scholar
  39. Ferrantelli, F., Hofmann-Lehmann, R., Rasmussen, R. A., Wang, T., Xu, W., Li, P. L., et al. (2003). Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. Aids, 17(3), 301–309.PubMedCrossRefGoogle Scholar
  40. Ferrantelli, F., Kitabwalla, M., Rasmussen, R. A., Cao, C., Chou, T. C., Katinger, H., et al. (2004). Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies—implications for acquired immunodeficiency syndrome vaccine. J Infect Dis, 189(1), 71–74.PubMedCrossRefGoogle Scholar
  41. Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., et al. (2007). Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med, 13(1), 100–106.PubMedCrossRefGoogle Scholar
  42. Fitzgerald, D. W., & Behets, F. M. (2003). Women's health and human rights in HIV prevention research. Lancet, 361(9351), 68–69.PubMedCrossRefGoogle Scholar
  43. Fitzgerald, D. W., Marotte, C., Verdier, R. I., Johnson, W. D., Jr., & Pape, J. W. (2002). Comprehension during informed consent in a less-developed country. Lancet, 360(9342), 1301–1302.PubMedCrossRefGoogle Scholar
  44. Fitzgerald, D. W., Pape, J. W., Wasserheit, J. N., Counts, G. W., Counts, G. W., & Corey, L. (2003). Provision of treatment in HIV-1 vaccine trials in developing countries. Lancet, 362(9388), 993–994.PubMedCrossRefGoogle Scholar
  45. Fleming, D. T., & Wasserheit, J. N. (1999). From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect, 75(1), 3–17.PubMedCrossRefGoogle Scholar
  46. Frazer, I. H., Cox, J. T., Mayeaux, E. J., Jr., Franco, E. L., Moscicki, A. B., Palefsky, J. M., et al. (2006). Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J, 25(2 Suppl), S65–81, quiz S82.PubMedGoogle Scholar
  47. Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., & Hayes, R. J. (2006). Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids, 20(1), 73–83.PubMedCrossRefGoogle Scholar
  48. Galvin, S. R., & Cohen, M. S. (2004). The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol, 2(1), 33–42.PubMedCrossRefGoogle Scholar
  49. Gao, F., Korber, B. T., Weaver, E., Liao, H. X., Hahn, B. H., & Haynes, B. F. (2004). Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines, 3(4 Suppl), S161–168.PubMedCrossRefGoogle Scholar
  50. Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., et al. (2002). Diversity considerations in HIV-1 vaccine selection. Science, 296(5577), 2354–2360.PubMedCrossRefGoogle Scholar
  51. Gouws, E., Williams, B. G., Sheppard, H. W., Enge, B., & Karim, S. A. (2002). High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion. J Acquir Immune Defic Syndr, 29(5), 531–535.PubMedGoogle Scholar
  52. Grassly, N. C., Lowndes, C. M., Rhodes, T., Judd, A., Renton, A., & Garnett, G. P. (2003). Modelling emerging HIV epidemics: the role of injecting drug use and sexual transmission in the Russian Federation, China and India. Int J Drug Policy, 14, 25–43.CrossRefGoogle Scholar
  53. Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., et al. (2007). Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet, 369(9562), 657–666.PubMedCrossRefGoogle Scholar
  54. Gray, R. H., Li, X., Wawer, M. J., Serwadda, D., Sewankambo, N. K., Wabwire-Mangen, F., et al. (2004). Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis, 189(7), 1209–1215.PubMedCrossRefGoogle Scholar
  55. Gray, R. H., Wawer, M. J., Brookmeyer, R., Sewankambo, N. K., Serwadda, D., Wabwire-Mangen, F., et al. (2001). Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet, 357(9263), 1149–1153.PubMedCrossRefGoogle Scholar
  56. Gregson, S., Nyamukapa, C. A., Garnett, G. P., Mason, P. R., Zhuwau, T., Carael, M., et al. (2002). Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet, 359(9321), 1896–1903.PubMedCrossRefGoogle Scholar
  57. Hinman, A. R., Orenstein, W. A., & Papania, M. J. (2004). Evolution of measles elimination strategies in the United States. J Infect Dis, 189(Suppl 1), S17–22.PubMedCrossRefGoogle Scholar
  58. HIV Vaccine Trials Network. (2006). HVTN Aug 2005 – July 2006 Evaluation Report. Seattle: HIV Vaccine Trials Network.Google Scholar
  59. Hoffman, I. F., Jere, C. S., Taylor, T. E., Munthali, P., Dyer, J. R., Wirima, J. J., et al. (1999). The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. Aids, 13(4), 487–494.PubMedCrossRefGoogle Scholar
  60. Howson, C. P., & Fineberg, H. V. (1992). Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. Jama, 267(3), 392–396.PubMedCrossRefGoogle Scholar
  61. HVTN. (2006a). A multicenter double-blind randomized placebo-controlled Phase IIB test-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Clade B-based Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1-uninfected adults in South Africa: HIV Vaccine Trials Network.Google Scholar
  62. HVTN. (2006b). HVTN Aug 2005 – July 2006 Evaluation Report. Seattle: HIV Vaccine Trials Network.Google Scholar
  63. HVTN. (2007). The Step Study: Vaccination and enrollment are discontinued. (Accessed November 25, 2007); Scholar
  64. IAVI. Treatment and Care Guidelines for IAVI Sponsored Trials, 2007, from Scholar
  65. Jaspan, H. B., Berwick, J. R., Myer, L., Mathews, C., Flisher, A. J., Wood, R., et al. (2006). Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health, 39(5), 642–648.PubMedCrossRefGoogle Scholar
  66. Jaspan, H. B., Cunningham, C. K., Tucker, T. J., Wright, P. F., Self, S. G., Sheets, R. L., et al. (2008). Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. J Acquir Immune Defic Syndr, 47(1), 86–92.Google Scholar
  67. Jenkins, D. (1996). A cold chain friendly to people … and the environment. Afr Health, 18(6), 19–20.PubMedGoogle Scholar
  68. Jewkes, R., Dunkle, K., Nduna, M., Levin, J., Jama, N., Khuzwayo, N., et al. (2006). Factors associated with HIV sero-status in young rural South African women: connections between intimate partner violence and HIV. Int J Epidemiol, 35(6), 1461–1468.PubMedCrossRefGoogle Scholar
  69. Jewkes, R., Levin, J., Mbananga, N., & Bradshaw, D. (2002). Rape of girls in South Africa. Lancet, 359(9303), 319–320.PubMedCrossRefGoogle Scholar
  70. Joseph, P., Schackman, B. R., Horwitz, R., Nerette, S., Verdier, R. I., Dorsainvil, D., et al. (2006). The use of an educational video during informed consent in an HIV clinical trial in Haiti. J Acquir Immune Defic Syndr, 42(5), 588–591.PubMedCrossRefGoogle Scholar
  71. Kahn, J. A. (2005). Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health, 37(6 Suppl), S10–16.PubMedCrossRefGoogle Scholar
  72. Kahn, J. A., Zimet, G. D., Bernstein, D. I., Riedesel, J. M., Lan, D., Huang, B., et al. (2005). Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health, 37(6), 502–510.PubMedCrossRefGoogle Scholar
  73. Kandathil, A. J., Ramalingam, S., Kannangai, R., David, S., & Sridharan, G. (2005). Molecular epidemiology of HIV. Indian J Med Res, 121(4), 333–344.PubMedGoogle Scholar
  74. Karon, J. M., Fleming, P. L., Steketee, R. W., & De Cock, K. M. (2001). HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health, 91(7), 1060–1068.PubMedCrossRefGoogle Scholar
  75. Korber, B., Gaschen, B., Yusim, K., Thakallapally, R., Kesmir, C., & Detours, V. (2001). Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull, 58, 19–42.PubMedCrossRefGoogle Scholar
  76. Kublin, J. G., Patnaik, P., Jere, C. S., Miller, W. C., Hoffman, I. F., Chimbiya, N., et al. (2005). Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet, 365(9455), 233–240.PubMedGoogle Scholar
  77. Lawn, S. D., Bekker, L. G., & Miller, R. F. (2005). Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis, 5(6), 361–373.PubMedCrossRefGoogle Scholar
  78. Lazcano-Ponce, E., Rivera, L., Arillo-Santillan, E., Salmeron, J., Hernandez-Avila, M., & Munoz, N. (2001). Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res, 32(3), 243–247.PubMedCrossRefGoogle Scholar
  79. Lehtinen, M., Apter, D., Dubin, G., Kosunen, E., Isaksson, R., Korpivaara, E. L., et al. (2006). Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS, 17(8), 517–521.PubMedCrossRefGoogle Scholar
  80. Lemckert, A. A., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., et al. (2005). Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol, 79(15), 9694–9701.PubMedCrossRefGoogle Scholar
  81. Letvin, N. L. (2005). Progress toward an HIV vaccine. Annu Rev Med, 56, 213–223.PubMedCrossRefGoogle Scholar
  82. Letvin, N. L. (2006). Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol, 6(12), 930–939.PubMedCrossRefGoogle Scholar
  83. Levine, M. M. (2003). Can needle-free administration of vaccines become the norm in global immunization? Nat Med, 9(1), 99–103.PubMedCrossRefGoogle Scholar
  84. Mbizvo, M. T., Machekano, R., McFarland, W., Ray, S., Bassett, M., Latif, A., et al. (1996). HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe. Aids, 10(8), 895–901.PubMedCrossRefGoogle Scholar
  85. McClelland, R. S., Wang, C. C., Mandaliya, K., Overbaugh, J., Reiner, M. T., Panteleeff, D. D., et al. (2001). Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. Aids, 15(1), 105–110.PubMedCrossRefGoogle Scholar
  86. McDougal, J. S., Parekh, B. S., Peterson, M. L., Branson, B. M., Dobbs, T., Ackers, M., et al. (2006). Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses, 22(10), 945–952.PubMedCrossRefGoogle Scholar
  87. McMichael, A. J. (2006). HIV vaccines. Annu Rev Immunol, 24, 227–255.PubMedCrossRefGoogle Scholar
  88. McMichael, A. J., & Hanke, T. (2003). HIV vaccines 1983–2003. Nat Med, 9(7), 874–880.PubMedCrossRefGoogle Scholar
  89. Mellors, J. W., Kingsley, L. A., Rinaldo, C. R., Jr., Todd, J. A., Hoo, B. S., Kokka, R. P., et al. (1995). Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med, 122(8), 573–579.PubMedGoogle Scholar
  90. Mills, E., Nixon, S., Singh, S., Dolma, S., Nayyar, A., & Kapoor, S. (2006). Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLoS Med, 3(3), e94.PubMedCrossRefGoogle Scholar
  91. Mullins, J. I., Nickle, D. C., Heath, L., Rodrigo, A. G., & Learn, G. H. (2004). Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines, 3(4 Suppl), S151–159.PubMedCrossRefGoogle Scholar
  92. NIH. (2007). Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial, 2007, from;jsessionid06A16494F781515A87BC F1C778CAC815?order=2Google Scholar
  93. NIAID. (2005). Clinical Research on HIV Vaccines Rockville. http://www.niaid.nih. gov/factsheets/clinrsch.htmGoogle Scholar
  94. Oberle, M. W., Rosero-Bixby, L., Lee, F. K., Sanchez-Braverman, M., Nahmias, A. J., & Guinan, M. E. (1989). Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Am J Trop Med Hyg, 41(2), 224–229.PubMedGoogle Scholar
  95. Page-Shafer, K., Saphonn, V., Sun, L. P., Vun, M. C., Cooper, D. A., & Kaldor, J. M. (2005). HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet, 366(9495), 1499–1503.PubMedCrossRefGoogle Scholar
  96. Pettifor, A. E., Kleinschmidt, I., Levin, J., Rees, H. V., MacPhail, C., Madikizela-Hlongwa, L., et al. (2005a). A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15–24 in South Africa: results of the baseline survey. Trop Med Int Health, 10(10), 971–980.CrossRefGoogle Scholar
  97. Pettifor, A. E., Rees, H. V., Kleinschmidt, I., Steffenson, A. E., MacPhail, C., Hlongwa-Madikizela, L., et al. (2005b). Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. Aids, 19(14), 1525–1534.CrossRefGoogle Scholar
  98. Pettifor, A. E., van der Straten, A., Dunbar, M. S., Shiboski, S. C., & Padian, N. S. (2004). Early age of first sex: a risk factor for HIV infection among women in Zimbabwe. Aids, 18(10), 1435–1442.PubMedCrossRefGoogle Scholar
  99. Pinkerton, S. D., Abramson, P. R., Kalichman, S. C., Catz, S. L., & Johnson-Masotti, A. P. (2000). Secondary HIV transmission rates in a mixed-gender sample. Int J STD AIDS, 11(1), 38–44.PubMedCrossRefGoogle Scholar
  100. Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., et al. (2006). Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis, 194(12), 1661–1671.PubMedCrossRefGoogle Scholar
  101. Pitisuttithum, P., Martin, M., Vanichseni, F., van Griensven, F., Tappero, J. W., Sangkum, E., et al. (2004). Social impact and harm among injecting drug users (IDUs) in a phase III HIV vaccine trial in Thailand. Paper presented at the XV International AIDS Conference, 2004 Bangkok, Thailand. Scholar
  102. Price, M. A., Zimba, D., Hoffman, I. F., Kaydos-Daniels, S. C., Miller, W. C., Martinson, F., et al. (2003). Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis, 30(6), 516–522.PubMedCrossRefGoogle Scholar
  103. Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature, 441(7090), 239–243.PubMedCrossRefGoogle Scholar
  104. Rosenberg, P. S., & Biggar, R. J. (1998). Trends in HIV incidence among young adults in the United States. Jama, 279(23), 1894–1899.PubMedCrossRefGoogle Scholar
  105. Schattner, A. (2005). Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine, 23(30), 3876–3886.PubMedCrossRefGoogle Scholar
  106. Schiffer, J. T., Metzger, D., Baral, S. D., Sirisanthana, T., Vitek, C., & Beyrer, C. (2007). HIV-1 Vaccine Efficacy Trials in Injecting Drug Users: Public Health, Investigational and Human Rights Rationales for their conduct. manuscript.Google Scholar
  107. Schleifer, R. (2005). Jamaica: report documents homophobia and violence. HIV AIDS Policy Law Rev, 10(1), 45–46.PubMedGoogle Scholar
  108. Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., et al. (1999). Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science, 283(5403), 857–860.PubMedCrossRefGoogle Scholar
  109. Serwadda, D., Gray, R. H., Sewankambo, N. K., Wabwire-Mangen, F., Chen, M. Z., Quinn, T. C., et al. (2003). Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis, 188(10), 1492–1497.PubMedCrossRefGoogle Scholar
  110. Sexton, J., Garnett, G., & Rottingen, J. A. (2005). Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis, 32(6), 351–357.PubMedCrossRefGoogle Scholar
  111. Shisana, O., Rehle, T., Simbayi, L. C., Parker, W., Zuma, K., Bhana, A., et al. (2005). South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2005. Cape Town: HSRC Press.Google Scholar
  112. Singh, M. (2006). No vaccine against HIV yet—are we not perfectly equipped? Virol J, 3, 60.PubMedCrossRefGoogle Scholar
  113. South African Medical Research Council. (2004) HIV Preventive Vaccine Research (Vol. 5).Google Scholar
  114. Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., et al. (2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med, 347(21), 1652–1661.PubMedCrossRefGoogle Scholar
  115. Sterling, T. R., Lyles, C. M., Vlahov, D., Astemborski, J., Margolick, J. B., & Quinn, T. C. (1999). Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis, 180(3), 666–672.PubMedCrossRefGoogle Scholar
  116. UNAIDS. (2006). AIDS epidemic update: special report on HIV/AIDS. Geneva: UNAIDS. Scholar
  117. Veazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., et al. (2003). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med, 9(3), 343–346.PubMedCrossRefGoogle Scholar
  118. Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J. G., Margolick, J. B., et al. (1998). Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. Jama, 279(1), 35–40.PubMedCrossRefGoogle Scholar
  119. Waibale, P., Bowlin, S. J., Mortimer, E. A., Jr., & Whalen, C. (1999). The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Int J Epidemiol, 28(2), 341–346.PubMedCrossRefGoogle Scholar
  120. Wasserheit, J. N. (2005). Paper presented at the AIDS Vaccine.Google Scholar
  121. Weiss, H. (2004). Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes, 11(Suppl 1), 24A–35A.PubMedGoogle Scholar
  122. WHO. (2001). Global prevalence and incidence of selected curable sexually transmitted infections. Geneva.Google Scholar
  123. WHO, & UNAIDS. (2007). Consultation on STI Interventions for preventing HIV: Appraisal of the Evidence. Geneva.Google Scholar
  124. Xiao, L., Owen, S. M., Rudolph, D. L., Lal, R. B., & Lal, A. A. (1998). Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha. J Infect Dis, 177(2), 437–445.PubMedCrossRefGoogle Scholar
  125. Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., et al. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. Jama, 296(8), 964–973.PubMedCrossRefGoogle Scholar

Copyright information

© Springer ScienceBusiness Media, LLC 2008

Authors and Affiliations

  • Ruanne V. Barnabas
    • 1
  • Ann C. Duerr
    • 1
  • Judith N. Wasserheit
    • 1
  1. 1.Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations